论文部分内容阅读
目的:主要研究了孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的临床效果。方法:选取我院于2014年12月-2015年12月间收治的74例咳嗽变异性哮喘患儿,随机将其分为治疗1组、治疗2组。其中治疗1组患儿37例,接受孟鲁司特钠联合布地奈德治疗;治疗2组患者37例,单方面接受布地奈德治疗,比较两组患儿治疗效果。结果:从此次研究结果来看,治疗1组患儿的临床治疗总有效率(36/37)明显优于治疗2组(27/37)97.29%>72.97%,两组结果相比,P<0.05。比较两组患儿咳嗽评分情况,治疗1组明显优于治疗2组,治疗后明显优于治疗前(P<0.05)。结论:孟鲁司特钠联合布地奈德在治疗小儿咳嗽变异性哮喘中的临床效果显著,具有疗效确切、见效快等优点,应该成为临床治疗的首选方法。
Objective: To study the clinical effect of montelukast combined with budesonide in the treatment of pediatric cough variant asthma. Methods: A total of 74 children with cough variant asthma admitted from December 2014 to December 2015 in our hospital were randomly divided into treatment group (1) and treatment group (2). Among them, 37 cases were treated in one group and received montelukast combined with budesonide; 37 cases in two groups were treated with budesonide unilaterally, and the therapeutic effect was compared between the two groups. Results: From the results of this study, the total effective rate (36/37) in treatment group 1 was significantly better than that in treatment 2 group (27/37), 97.29%> 72.97%, P < 0.05. Comparing the scores of cough in both groups, the treatment group 1 was obviously better than the treatment group 2, which was obviously better than before treatment (P <0.05). Conclusion: The combination of montelukast and budesonide has significant clinical effect in the treatment of pediatric cough variant asthma, which has the advantages of exact effect and quick response, and should be the first choice of clinical treatment.